Evidence map›Paper›PMID 36853451›Full record

ArticleInternational journal of hematology2023

Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.

Naoki Miyashita, Masahiro Onozawa, Shota Yoshida, Hiroyuki Kimura, Shogo Takahashi, Shota Yokoyama, Toshihiro Matsukawa, Shinsuke Hirabayashi, Shinichi Fujisawa, Akio Mori and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. CD7-positive leukemic blasts withFrontiers in oncology · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 14 institutions in 1 country.

Naoki MiyashitaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Masahiro OnozawaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan. onozawa@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0001-9267-2864
Shota YoshidaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Hiroyuki KimuraDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Shogo TakahashiDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Shota YokoyamaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Toshihiro MatsukawaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Shinsuke HirabayashiDepartment of Pediatrics, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Shinichi FujisawaDivision of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan.
Akio MoriBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Yasutaka KakinokiDepartment of Hematology, Asahikawa City Hospital, Asahikawa, Japan.
Yutaka TsutsumiDepartment of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
Satoshi YamamotoDepartment of Hematology, Sapporo City General Hospital, Sapporo, Japan.
Takuto MiyagishimaDepartment of Hematology, Kushiro Rosai Hospital, Kushiro, Japan.
Takahiro NagashimaDepartment of Internal Medicine/General Medicine, Kitami Red Cross Hospital, Kitami, Japan.
Makoto IbataDepartment of Hematology, Sapporo Kosei General Hospital, Sapporo, Japan.
Kentaro WakasaDepartment of Hematology, Obihiro Kosei Hospital, Obihiro, Japan.
Yoshihito HaseyamaDepartment of Hematology, Tonan Hospital, Sapporo, Japan.
Katsuya FujimotoDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Toshimichi IshiharaDepartment of Hematology, Kin-Ikyo Chuo Hospital, Sapporo, Japan.
Hajime SakaiDepartment of Hematology, Teine Keijinkai Hospital, Sapporo, Japan.
Takeshi KondoBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 0608638, Japan.
Hokkaido University · JPAsahikawa City Hospital · JPHakodate National Hospital · JPHokkaido University Hospital · JPJapanese Red Cross Hokkaido College of Nursing · JPKin-ikyo Chuo Hospital · JPKushiro Rosai Hospital · JPNational Hospital Organization Hokkaido Medical Center · JPObihiro Kosei General Hospital · JPSapporo City General Hospital · JPSapporo Hokuyu Hospital · JPSapporo Kosei General Hospital · JPTeine Keijinkai Hospital · JPTonan Hospital · JP

Funding

Japan Society for the Promotion of Science Grant-in-Aid for scientific research (20K08745)
6 · The paper itself

Abstract

Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML.

Indexed as

Leukemia, Myeloid, AcuteNuclear ProteinsCCAAT-Enhancer-Binding Proteinsfms-Like Tyrosine Kinase 3HumansMutationNucleophosminPrognosisCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3Nuclear ProteinsNucleophosminAMLCEBPA bZIPFLT3Hokkaido Leukemia Net (HLN)North Japan Hematology Study Group (NJHSG)NPM1

Identifiers

PMID36853451
OpenAlexW4322616994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.